Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AI-Guided vs Standard Anti-VEGF Treatment in nAMD
NCT05093374Phase 4Recruiting
- Sponsor
- Medical University of Vienna
- Start
- Mar 2021
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Number of injections at 12 months. Started Mar 2021; status: recruiting.
02
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05093374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05093374.